Litcius/Paper detail

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Émeric Boisteau, Alexandra Lespagnol, Marie de Tayrac, Sébastien Corre, Anthony Perrot, Nathalie Rioux-Leclercq, Severine Martin‐Lannerée, Pascal Artru, P. Chalabreysse, Pierre-Guillaume Poureau, Laurent Doucet, Dahna Coupez, Jaafar Bennouna, Céline Bossard, Romain Coriat, Frédéric Beuvon, Lucile Bauguion, F. Leclair, Romain Chautard, Thierry Lecomte, Serge Guyétant, Romain Desgrippes, D Grasset, Hélène Lhostis, Karine Bouhier‐Leporrier, Frédéric Bibeau, Julien Edeline, Marie‐Dominique Galibert, Astrid Lièvre

2022Clinics and Research in Hepatology and Gastroenterology12 citationsDOI

Topics & Concepts

BevacizumabMedicineColorectal cancerInternal medicineOncologyOverall survivalFirst lineGastroenterologyCancerChemotherapyColorectal Cancer Treatments and StudiesMicroRNA in disease regulationCircular RNAs in diseases
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer | Litcius